Search the Newsreel

Myriad Genetics (MYGN): Glenview Capital and Larry Robbins report exit from stake

Glenview Capital Management and Larry Robbins have reported that they no longer hold a significant ownership stake in Myriad Genetics (MYGN). An SEC filing (SCHEDULE 13G/A) indicates that as of June 30, 2026, they beneficially own 0 shares, representing 0% of the outstanding common …

MacroGenics (MGNX) gains $86M on CDMO sale as royalties and milestones rise

MacroGenics reported a Q2 2026 profit driven by an $86.1 million gain from the sale of its CDMO operations for approximately $119.6 million. The company's total revenue significantly increased to $32.8 million due to a $24.5 million milestone from Sanofi and higher ZYNYZ royalty …

Global X Management (GEL) reports 6.32% beneficial stake in Genesis Energy units

Global X Management Company LLC has reported a beneficial ownership of 7,722,608 common units in Genesis Energy, L.P., which constitutes a 6.32% stake. This ownership is managed through its role as an investment adviser to the Global X MLP ETF. The acquisition was part …

Allogene Therapeutics (ALLO): Frazier funds disclose 5.6% ownership and affiliated stakes

Frazier Life Sciences Public Fund, L.P. has reported a 5.6% ownership stake in Allogene Therapeutics (ALLO), holding 19,445,046 shares. Other affiliated Frazier funds also hold additional stakes, bringing the total reported beneficial ownership by various Frazier entities and individuals to a significant portion of …

Genpact (NYSE: G) CFO sells 5,900 shares, retains 176,027 holding

Genpact LTD's Chief Financial Officer, Michael Hal Weiner, sold 5,900 Common Shares on August 13, 2026, at a price of $34.04 per share. Following this transaction, Weiner directly holds 176,027 Common Shares, including 1,591 shares acquired through the Genpact Employee Stock Purchase Plan (ESPP). …

Company G (G) insider plans NYSE sale of 14,972 shares via Morgan Stanley

An insider at Company G (G) has filed a Form 144 to sell 14,972 common shares on the NYSE through Morgan Stanley Smith Barney LLC. The aggregate market value of these shares is approximately $510,558.52, with the planned sale date set for August 14, …

enGene Holdings (ENGN): Venrock investor group reports 0.0% stake and no voting power

An amended Schedule 13G/A filing for enGene Holdings Inc. (ENGN) indicates that a group of Venrock-affiliated investment entities and two individuals now report a 0.0% beneficial ownership of the company's Common Shares as of June 30, 2026. This means the group, previously significant holders, …

First Light Asset Management (AXGN) discloses 7.58% Axogen stake for Mathew Arens

First Light Asset Management, LLC and Mathew P. Arens have filed an amended Schedule 13G disclosing their beneficial ownership in Axogen, Inc. First Light Asset Management may be deemed to beneficially own 3,746,380 shares (6.97% of the class), while Mathew P. Arens may be …

Gen Digital Inc. stock underperforms Friday when compared to competitors

Gen Digital Inc. (GEN) stock dropped 3.69% on Friday, closing at $28.48, and underperformed against a declining market where the S&P 500 and Dow Jones also fell. The stock is now 11.25% below its 52-week high of $32.09, which was reached on the same …

Cathay General Bancorp Declares $0.38 Per Share Dividend

Cathay General Bancorp (Nasdaq: CATY) announced that its Board of Directors has declared a cash dividend of $0.38 per common share. The dividend is payable on September 8, 2026, to stockholders of record as of August 28, 2026. Cathay General Bancorp is the holding …

NeoGenomics (NEO) stake tops 8% for First Light’s Mathew Arens

Mathew P. Arens and First Light Asset Management, LLC have reported their beneficial ownership in NeoGenomics, Inc. through a Schedule 13G/A filing. Arens beneficially owns 8.37% of NeoGenomics' common stock, totaling 10,759,586 shares, which includes holdings through First Light, direct shares, and a joint …

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG

This article announces that QIAGEN N.V. has received a notification from the AFM (the Netherlands Authority For the Financial Markets) regarding a voting rights announcement. Wellington Management Group LLP reported a transaction on August 12, 2026, indicating they hold 4.96% of the voting rights …

Diana Shipping Inc. 撤回了收購 Genco Shipping & Trading 的要約，原因是 Genco 董事會提出了無理要求。

Diana Shipping Inc. 已撤回對 Genco Shipping & Trading 的收購要約，理由是 Genco 董事會提出了不合理的要求。Diana Shipping 認為 Genco 的要求過高且不符合其股東的最佳利益，因此決定終止這項交易。此舉反映了雙方在交易條件上未能達成一致。

Vistagen Therapeutics (VTGN) investor Chen Yu reports 6.7% warrant-based stake

Chen Yu, through TCG Crossover funds, has reported a 6.7% warrant-based stake in Vistagen Therapeutics (VTGN) via an amended Schedule 13G/A filing. TCG Crossover I holds 1.8% and TCG Crossover II holds 5.1%, with Chen Yu being the sole managing member of both general …

Vistagen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026

Groundbreaking takes place for NexGen Energy’s uranium mine project

NexGen Energy Ltd. has officially started construction on its Rook I uranium project in northwest Saskatchewan, marking a significant milestone after years of planning and engagement. The $2.2 billion project is expected to produce 30 million pounds of uranium annually and aims to create …

Genasys Inc. remains a Hold due to unprofitable core business outside Puerto Rico project.

Genasys Inc. is currently rated as a Hold because its core business is unprofitable, despite a temporary boost from a Puerto Rico project. This project is now paused due to issues with receivables and liquidity, exposing the company's weak financial fundamentals. Outside of Puerto …

Genasys Ex-Puerto Rico Quarter Shows How Dire Its Situation Is (NASDAQ:GNSS)

Genasys Inc. (GNSS) is rated a Hold due to its core business being deeply unprofitable outside of the Puerto Rico project. While recent profitability stemmed from this project, liquidity issues have paused it, revealing weak fundamentals. The company faces a strained balance sheet, costly …

Should I Buy NXE (NexGen Energy Ltd.) | AI Analysis, Technical & News Insights

Myriad Genetics (MYGN): Vestal Point Capital discloses 6.1% stake in 13G filing

Vestal Point Capital, LP and its Chief Investment Officer Ryan Wilder have disclosed a 6.1% stake in Myriad Genetics, Inc. (MYGN) through a Schedule 13G filing. The reporting group beneficially owns 5,735,000 shares of common stock, representing 6.1% of the 94,448,210 outstanding shares as …

IGIC|International General Insurance Holdings Ltd|Price:27.260|Chg%:+0.350

This article provides a detailed financial overview of International General Insurance Holdings Ltd (IGIC), including its live stock price, key figures, and technical analysis. The company, based in Jordan, specializes in commercial insurance and reinsurance across various segments. Analysts currently rate IGIC as a …

Cogent Communications (NASDAQ:CCOI) Trading 7.5% Higher - Here's Why

Cogent Communications (NASDAQ:CCOI) shares rose 7.5% in mid-day trading despite recent analyst downgrades and a pending securities class-action lawsuit. Analysts have lowered price targets, with a consensus "Hold" rating and an average target of $21.05. The lawsuit alleges misleading disclosures regarding demand, growth, and …

Precigen (NASDAQ:PGEN) Trading Down 5.5% - What's Next?

Precigen (NASDAQ:PGEN) saw its shares drop by 5.5% despite reporting stronger-than-expected quarterly results, with EPS of $0.05 against an estimated loss of $0.01, and revenue soaring by 6,322.7% year-over-year to $54.98 million. The biotechnology company maintains a "Moderate Buy" consensus rating with an average …

T. Rowe Price (ARGX) discloses 2.68M argenx SE ADRs with 4.3% ownership

T. Rowe Price Associates, Inc. has disclosed a beneficial ownership of 2,675,457 argenx SE ADRs as of June 30, 2026, representing a 4.3% stake. The firm holds sole voting power over 2,649,465 ADRs and sole dispositive power over all 2,675,457 ADRs, explicitly denying beneficial …

Bernstein Lifts Regeneron Price Target to $756, Stays on Sidelines

Bernstein has raised its price target for Regeneron Pharmaceuticals to $756 from $753, while maintaining a Market Perform rating, indicating a slightly more positive near-term outlook but not a fundamental shift in its investment thesis. This new target remains below the Wall Street consensus …

UBS Group Has Lowered Expectations for Cogent Communications (NASDAQ:CCOI) Stock Price

Enterprise value to EBITDA forward of Agency Group Australia Ltd – ASX:AU1

American Century group reports 5.4% Emergent BioSolutions (EBS) ownership on Schedule 13G

American Century ETF Trust and its affiliates, including American Century Investment Management, Inc., American Century Companies, Inc., and the Stowers Institute for Medical Research, have reported passive ownership stakes in Emergent BioSolutions Inc. (EBS) common stock via a Schedule 13G filing. The ETF Trust …

General Motors (NYSE:GM) Declares Dividend As Capital Discipline Takes Center Stage

General Motors has declared a cash dividend, signaling confidence in its financial health and a commitment to capital discipline. The company is focusing on higher-margin vehicles like trucks and large SUVs to fund its electric vehicle transition while carefully managing spending. This strategy aims …

Gentex (GNTX): American Century group discloses 5.2% beneficial ownership stake

American Century Investment Management, Inc., American Century Companies, Inc., and the Stowers Institute for Medical Research have collectively reported a 5.2% beneficial ownership stake in Gentex Corporation (GNTX). This group owns 11,025,677 shares of Gentex common stock as of June 30, 2026, holding sole …

Bionano Genomics (BNGO) investor discloses 9.9% position via warrants

CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a 9.9% beneficial ownership in Bionano Genomics (BNGO) through warrants. This position, amounting to 1,307,135 shares, is subject to ownership caps of 4.99% and 9.99% for different portions of the warrants. The ownership percentage …

NexGen Energy: Construction Turns Regulatory Scarcity Into A Uranium Moat (NYSE:NXE)

NexGen Energy has begun major construction on its Rook I uranium project after securing final federal approval, positioning itself as a crucial Western uranium supplier. The company's competitive advantage lies in its timely progress, as other projects face permitting delays, and its strong liquidity …

Genmab A/S (GMAB): Orbis and Allan Gray report 5.3% beneficial ownership stake

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly reported a beneficial ownership stake of 5.3% in Genmab A/S (GMAB), totaling 3,328,505 Ordinary Shares. This includes both direct Ordinary Shares and American Depositary Shares (ADS). The filing indicates that while they …

Vistagen (VTGN) narrows quarterly loss, eyes FDA path after mixed fasedienol data

Vistagen (VTGN) reported a narrower net loss of $13.0 million for Q1 FY2027, an improvement from $15.1 million in the prior-year quarter, largely due to increased revenue and reduced R&D and G&A expenses. While its lead drug fasedienol missed its primary endpoint in the …

VistaGen Therapeutics earnings missed by $0.05, revenue topped estimates

Vistagen Therapeutics Releases Q1 2027 Financial Results

Vistagen Therapeutics reported a narrower loss for Q1 fiscal 2027, with a basic and diluted loss of $0.30 per share and a net loss of $13.0M. The company saw a significant revenue increase to $1.5M, up 504.9% year-over-year, as it continues to develop therapies …